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	Abstract	
Background:	 Atypical	 parkinsonian	 conditions	 such	 as	 multiple	 system	 atrophy	 (MSA),	progressive	supranuclear	palsy	(PSP),	corticobasal	syndrome	(CBS)	and	Dementia	with	Lewy	bodies	 (DLB)	 comprise	 10-15%	 of	 parkinsonian	 syndromes.	 Misdiagnosis	 with	 Parkinson	disease	 (PD)	 and	within	 the	 entities	 is	 common,	 given	 the	 absence	 of	 reliable	 biomarkers.	However	a	correct	diagnosis	is	not	only	important	in	clinical	practice,	but	also	crucial	for	any	trial	attempting	to	identify	biomarkers	or	new	treatments.		
Methods:	Consecutive	patients,	who	were	either	referred	with	a	diagnosis	of	a	particular	AP	by	a	neurologist,	or	where	a	movement	disorder	specialist	at	Queen	Square	considered	such	a	diagnosis,	were	included	and	the	medical	records	were	reviewed	retrospectively.	We	applied	each	set	of	current	diagnostic	research	criteria	to	the	respective	cohort	to	see	which	features	fit	in	and	if	there	are	atypical	features	“outside”	the	classic	definition.		
Results:	 Sixty-nine	 patients	 were	 recruited	 clinically	 presenting	 with	 one	 of	 the	 following	phenotypes:	 14	MSA,	 24	PSP,	 19	CBS	 and	12	DLB.	Up	 to	 49%	 showed	 additional	 “atypical”	features	and	approximately	10%	eventually	received	an	alternative	diagnosis,	in	half	of	whom	this	was	based	on	genetic	testing.	
Conclusions:	 In	 a	 subset	 of	 our	 patients,	 despite	 the	 final	 diagnosis	 of	 an	 AP	 being	maintained,	there	were	additional	“atypical”	features.	It	remains	to	be	seen	if	these	reflect	the	clinical	heterogeneity	of	APs,	or	should	prompt	a	search	for	an	alternative	diagnosis.	A	change	in	 terminology	 using	 phenotypic	 descriptors	 (e.g.	 MSA	 syndrome)	 rather	 than	 aetiological	labels,	as	already	applied	for	CBS,	could	therefore	be	a	consideration	for	all	the	APs.		
	
	1.	Introduction	
Atypical	 parkinsonism	 (AP)	 refers	 to	 a	 group	 of	 disorders	 including	 multiple	 system	atrophy	 (MSA),	progressive	supranuclear	palsy	 (PSP),	 corticobasal	 syndrome	(CBS)	and	dementia	with	Lewy	bodies	 (DLB),	which	account	 for	up	 to	10-15%	of	all	parkinsonian	syndromes	 [1].	Given	 the	 lack	of	diagnostic	biomarkers,	 a	definite	diagnosis	of	APs	 can	only	 be	 made	 post	 mortem	 [1].	 Nonetheless,	 the	 classical	 AP	 phenotypes	 have	 been	delineated,	 and	 physicians	 are	 now	 familiar	 with	 such	 clinical	 templates,	 using	 them	routinely	for	the	diagnosis	of	these	disorders.	However,	there	is	increasing	evidence	that:	I)	 APs	 can	 clinically	 overlap	 [2,3];	 II)	 some	patients	with	 a	 pathological	 diagnosis	 for	 a	certain	 AP	 have	 “atypical”	 clinical	 presentations	 [2-5];	 and	 III)	 a	 number	 of	 newly	discovered	genetic	conditions	might	share	some	clinical	features	with	the	“classical	APs”	(therefore	 being	 referred	 to	 as	 “AP-look-alikes”)	 [6].	 For	 example,	 patients	 with	Dynactin1	(DCTN1)	or	microtubule-associated	protein	tau	(MAPT)	mutations	can	present	with	 a	 supranuclear	 gaze	 palsy	 and	 parkinsonism,	 as	 in	 PSP,	 although	 there	 may	 be	additional	features	atypical	for	PSP,	and	also	these	cases	might	be	younger	at	onset	than	classic	PSP.	All	 these	factors	might	contribute	to	the	relatively	high	rate	of	misdiagnosis	[1],	 hence	 hampering	 the	 identification	 of	 homogenous	 groups	 of	 patients	 for	 future	research	 on	 the	 pathophysiology	 of,	 and	 putative	 neuro-protective	 interventions	 for,	these	disorders.	Hence	in	a	previous	review	article	we	had	introduced	the	term	“atypical”	atypical	parkinsonism	 to	highlight	 such	 cases	 [6].	Here	we	are	 reappraising	 the	 clinical	features	and	diagnostic	outcomes	of	a	large	series	of	AP	patients.	
	
	2.	Materials	and	Methods	
We	 included	 consecutive	 patients	 referred	 to	 us	 by	 other	 neurologists	 with	 a	 working	diagnosis	 of	MSA,	 PSP,	 CBS,	 or	DLB	between	 January	 2013	 and	May	2015	 as	 a	 tertiary	referral.	 For	 each	 AP	 patient,	 clinical	 details	 were	 recorded	 on	 a	 proforma	 based	 on	current	 diagnostic	 research	 criteria	 [7-11].	 For	 PSP,	 two	 different	 proformas	 based	 on	NINDS	[10]	and	NNIPPS	[11]	sets	of	criteria	were	used.	Medical	records	were	reviewed	retrospectively	 and	 the	 clinical	 findings	were	 recorded	as	present	or	 absent	during	 the	first	 examination	 at	 our	 centre.	 Additional	 clinical	 findings	 (e.g.,	 not	 mentioned	 in	 the	research	criteria)	were	also	gathered.	Finally,	 imaging	 findings	and	results	of	additional	investigations,	including	genetic	testing	where	available,	performed	during	the	diagnostic	work-up	were	also	collected.	The	final	diagnosis	made	at	our	center	was	used	to	classify	patients	as	described	in	details	below.	
For	 the	 aim	 of	 the	 current	 study,	 for	 each	 AP	 patients	 were	 allocated	 into	 two	 main	groups	 according	 to	 whether	 or	 not	 they	 fulfilled	 the	 research	 criteria	 when	 first	attending	our	clinic	(e.g.,	group	A:	fulfilling	the	criteria;	and	B:	not	fulfilling	the	criteria).	For	 each	 group	 (e.g.	 Group	 A	 and	 B),	 patients	were	 further	 divided	 into	 different	 sub-groups	 according	 to	 the	 final	 working	 diagnosis	 and	 the	 presence	 of	 atypical	 features	(either	clinical	or	based	on	the	results	of	additional	investigations)	collected	throughout	a	mean	 follow-up	of	1.5	years	 (range:	6	months-2.5	years).	For	 the	aims	of	 the	study,	we	considered	 features	as	 “atypical”,	 if	 they	are	not	 classically	described	 in	a	particular	AP	and	 were	 judged	 too	 prominent	 to	 be	 “allowed”	 in	 that	 form	 of	 AP	 (for	 example	prominent	 cognitive	 dysfunction	 in	 MSA).	 Accordingly,	 groups	 A	 and	 B	 were	 further	stratified:		group	A1),	patients	fulfilling	the	criteria	of	a	particular	AP	and	being	“typical”;	A2),	patients	having	 “atypical”	 features	despite	 fulfilling	 the	criteria	 for	a	particular	AP;	
	A3)	patients	 receiving	an	alternative	diagnosis,	when	 initially	 fulfilling	 the	criteria	 for	a	particular	AP;	B1)	patients	not	fulfilling	 the	criteria	 for	a	particular	AP	and	receiving	an	alternative	diagnosis;	and	group	B2)	patients	not	fulfilling	the	criteria	but	still	carrying	a	working	 diagnosis	 for	 that	 particular	 AP.	 A	 flowchart	 describing	 the	 study	 design	 is	provided	in	figure	1.		
Given	the	retrospective	nature	of	the	study	and	the	relatively	low	numbers	of	patients	in	each	 sub-group,	 statistical	 analyses	 were	 not	 possible.	 Written	 informed	 consent	 was	obtained	from	all	patients	on	an	ethics	committee	approved	movement	disorder	research	form.	
3.	Results		A	total	of	69	patients	were	recruited	-	12	with	a	working	diagnosis	of	DLB,	14	MSA,	24	PSP,	and	19	CBS.	Table	1	provides	demographics	and	main	clinical	features	of	the	entire	cohort.	
3.1	Dementia	with	Lewy	bodies	presentation	
Applying	 the	 DLB	 research	 criteria,	 eight	 patients	 out	 of	 12	 fulfilled	 the	 criteria	 for	probable	DLB	(group	A),	while	the	remaining	four	did	not	because	of	the	lack	of	cognitive	impairment	occurring	one	year	before	or	after	the	motor	symptom	onset	(group	B).		
Among	 the	 patients	 fulfilling	 the	 criteria,	 three	 had	 a	 typical	 phenotype	 (group	 A1),	whereas	four	had	additional	“atypical”	features	(table	2),	thus	falling	into	group	A2.	These	included	two	with	abnormal	eye	movements	reminiscent	of	PSP	(slow	vertical	saccades	or	 up-gaze	 restriction	 deemed	 excessive	 for	 age)	 and	 another	 two	with	 limb	weakness	and	an	associated	head-drop,	which	led	us	to	perform	additional	genetic	analyses.	Of	the	
	latter	 two,	 one	 was	 found	 to	 be	 heterozygous	 for	 the	 c.1399G>A	 POLG	 mutation.	 The	second	 was	 detected	 to	 have	 asymmetric	 atrophy	 of	 the	 hippocampi	 and	 given	 the	
possible	 family	 history	 of	 her	 mother	 developing	 cognitive	 problems	 in	 her	 eighties,	genetic	testing	was	pursued.	She	was	found	to	carry	the	c.1216C>T	mutation	of	the	MAPT	gene,	thus	leading	to	a	definitive	alternative	diagnosis,	although	the	criteria	for	probable	DLB	were	initially	fulfilled	(group	A3).		
In	 group	 B,	 all	 patients	 (n=4)	 had	 a	 final	working	 diagnosis	 of	 DLB.	 (See	 figure	 1A	 for	detailed	sub-classification	of	“DLB-group”).	
3.2	Multiple	System	Atrophy	presentation		
Applying	 the	 research	 diagnostic	 criteria,	 a	 total	 of	 12	 patients	 (Group	 A)	 fulfilled	 the	criteria,	 2	 patients	 for	 possible	 and	 10	 for	 probable	MSA.	Of	 these,	 5	 had	 predominant	cerebellar	 features	 (MSA-C)	 while	 7	 had	 predominant	 parkinsonian	 features	 (MSA-P).	Within	this	group,	despite	2	patients	having	a	typical	phenotype,	the	large	majority	(up	to	75%)	had	additional	“atypical”	features	(table	2).	Namely,	two	patients	had	“atypical”	eye	movements	 (one	with	 slow	 vertical	 saccades	 and	 1	with	 the	 “round	 the	 houses”	 sign),	three	 had	 marked	 freezing	 of	 gait,	 one	 visual	 hallucinations	 unrelated	 to	 drugs,	 one	significant	 cognitive	 impairment	on	neuropsychometry	 (not	 fulfilling	dementia	 criteria)	and	three	had	a	positive	family	history	of	dementia	(2)	and	PSP	(1).	Of	interest,	among	the	10	patients	fulfilling	the	criteria	but	having	atypical	clinical	features,	one	MSA-P	case	had	a	 negative	 DaTSCAN	 and	 another	 one	 had	 an	 “atypical”	 MRI	 (generalised	 volume	 loss,	signal	 change	 in	 the	 splenium	 and	 thalamus	 and	 frontotemporal	 atrophy).	 Another	patient	 in	 this	 group	 had	 the	 middle	 cerebellar	 peduncle	 (MCP)	 sign	 on	 MRI.	 Despite	having	been	occasionally	reported	 in	MSA,	 this	 finding	along	with	progressive	cognitive	
	decline,	 led	 to	 additional	 genetic	 investigations	 and	 he	 was	 found	 to	 be	 carrier	 of	 the	
FMR1	premutation	(90	CGG	repeats),	thus	eventually	falling	into	the	Group	A3.		
Finally,	two	presenting	with	a	combination	of	parkinsonism	and	cerebellar	signs,	did	not	fulfil	the	criteria	for	MSA	(lack	of	autonomic	dysfunction)	and	they	were	eventually	given	a	 working	 diagnosis	 of	 Parkinsonism-Ataxia	 Syndrome	 (group	 B1).	 	 (See	 figure	 1B	 for	detailed	sub-classification	of	“DLB-group”).	
	
3.3	Progressive	Supranuclear	Palsy	presentation	
For	the	24	patients	within	the	PSP	group,	the	NINDS	and	the	NNIPPS	diagnostic	criteria	were	applied	separately.	Applying	the	NINDS	criteria,	four	fitted	the	criteria	for	probable	and	one	for	possible	PSP,	whereas	19	patients	did	not	fit	the	criteria	(among	whom	nine	lacked	the	core	criterion	of	prominent	postural	 instability	and	falls	within	the	 first	year	from	 onset	 and	 eight	 had	 at	 least	 one	 of	 the	 exclusion	 criteria).	 Applying	 the	 NNIPPS	criteria,	for	five	patients	the	diagnosis	of	PSP	was	applicable,	while	within	the	group	not	fulfilling	the	NNIPPS	criteria	(n=19),	11	did	not	meet	the	core	criteria	and	9	had	at	least	one	 exclusion	 criterion,	 namely	 rest	 tremor	 (n=4),	 disease	 duration	 >8	 years	 (n=3)	 or	signs	of	CBS	(n=6).	When	considering	the	overlap	between	the	two	sets	of	criteria,	only	2	patients	fulfilled	both,	while	none	of	the	possible	PSP	subjects	(according	to	the	NINDS)	fulfilled	the	NNIPPS	criteria	(figure	2).	
Subjects	were	subsequently	sub-divided	according	to	whether	(n=8,	group	A)	or	not	(n=	16,	 group	B)	 they	 fitted	 either	 of	 the	 two	 sets	 of	 criteria.	 Among	 the	 group	A	 patients,	while	five	patients	had	a	typical	phenotype,	the	other	three	showed	additional	“atypical”	features	 (group	A2)	 including	 pyramidal	 signs	 and	 cerebellar	 dysfunction	 (table	 3).	 On	
	the	other	hand,	among	the	patients	not	fulfilling	the	criteria	(n=16;	group	B),	seven	(44%)	received	an	alternative	diagnosis	after	an	extensive	work-up	(group	B1),	three	of	whom	carried	specific	genetic	mutations	(1	polymerase	gamma	(POLG),	1	proganulin	(PRGN),	1	
DCTN1),	one	was	eventually	diagnosed	with	Fahr’s	disease,	and	three	showed	extensive	pyramidal	 signs	 and	 marked	 cognitive	 impairment	 suggestive	 of	 a	 frontotemporal	dementia	with	motor	 neuron	 disease	 spectrum.	 The	 remaining	 nine	 patients	were	 still	carrying	a	working	diagnosis	of	PSP,	although	not	fulfilling	the	criteria	(group	B2).	Five	of	them	 had	 a	 clinical	 phenotype	 considered	 typical	 for	 PSP	 (e.g.	 backward	 falls	 and	supranuclear	 gaze	 palsy	 (SNGP)),	 but	 showed	 additional	 CBS-like	 features	 that	 are	currently	 considered	an	exclusion	criterion	 for	 the	diagnosis	according	 to	both	sets.	 	 In	one	of	the	remaining	four	patients	in	group	B2,	post-mortem	examination	was	available	confirming	 the	 diagnosis	 of	 PSP.	 (See	 figure	 1C	 for	 detailed	 sub-classification	 of	 “DLB-group”).	
3.4	Corticobasal	Syndrome	
Nineteen	patients	were	 included	with	a	referral	diagnosis	of	CBS	 -	15	had	a	classic	CBS	phenotype,	 one	presented	with	 a	nonfluent/agrammatic	 variant	of	primary	progressive	aphasia,	and	three	presented	with	a	CBS/PSP-overlap-syndrome	(e.g.	showing	additional	vertical	supranuclear	gaze	palsy).	Seventeen	of	 them	fulfilled	current	criteria	(group	A),	nine	 of	 whom	 fulfilled	 possible	 and	 8	 probable	 CBS	 criteria.	 Nonetheless,	 while	 eight	patients	 had	 a	 “typical”	 phenotype	 (group	 A1),	 seven	 showed	 additional	 “atypical”	features	(detailed	in	table	2;	group	A2).	Two	eventually	received	an	alternative	diagnosis	(group	A3)	since	 there	were	no	signs	of	parkinsonism	(despite	 the	referral	diagnosis	of	CBS)	and	there	was	evidence	of	marked	posterior	cortical	atrophy	on	imaging,	so	that	the	
	patients	 were	 diagnosed	 with	 Benson’s	 syndrome	 (posterior	 cortical	 atrophy;	 atypical	variant	of	Alzheimer	disease).	




Our	results	show	that	the	current	criteria	are	too	restrictive	and	“fitting”	patients	into	the	existing	 boxes	might	 lead	 to	misdiagnosis:	 I)	 A	 number	 of	 patients	 carrying	 a	working	diagnosis	of	AP	might	in	fact	have	a	different	underlying	condition;	II)	Among	the	patients	for	whom	 the	 clinical	 diagnosis	 of	 a	 specific	AP	would	 be	 appropriate	 according	 to	 the	research	diagnostic	criteria,	a	proportion	have	additional	“atypical”	features,	which	raises	the	question	as	to	whether	they	should	cast	doubt	on	the	diagnosis	or,	conversely,	expand	the	phenotype	of	each	AP;	and	III)	Some	patients	with	a	phenotype	suggestive	of	a	specific	AP	do	not	 fulfil	 the	diagnostic	criteria,	but	might	still	actually	have	the	condition,	which	underlines	the	relatively	low	sensitivity	of	the	existing	criteria	used	for	AP	syndromes.		
There	 is	 increasing	evidence	 that	 there	are	some	disorders	mimicking	APs,	hence	being	referred	 as	 AP-look-alikes	 or	 AP-phenocopies.[6,13-16]	 This	 was	 the	 case	 in	approximately	 5%	our	 cohort.	 In	 some	of	 these	patients,	 there	was	 a	 definitive	 genetic	diagnosis,	 indicating	the	 initial	working	diagnosis	was	wrong,	even	though	they	fulfilled	
	the	 respective	 research	criteria.	However,	 in	a	proportion	of	patients	with	a	phenotype	suggestive	 of	 one	 of	 the	 APs	 there	 were	 some	 “red	 flags”,	 including	 a	 positive	 family	history	 (e.g.,	 patients	 with	DCTN1	 and	MAPT	 mutations),	 a	 “too-long”-standing	 history	(e.g.	 patient	with	FMR1	 premutation),	 and	 associated	 clinical/radiological	 features	 (e.g.	severe	depression	in	the	patient	with	DCTN1	mutation;	subtle	hippocampal	atrophy	in	the	patient	carrying	the	MAPT	mutation;	prominent	cognitive	impairment	and	MCP	sign	in	the	patient	with	FMR1	premutation),	which	prompted	us	to	look	for	an	alternative	diagnosis.		This	would	suggest	that,	despite	the	core	clinical	phenotype	being	suggestive	of	one	of	the	APs,	 one	 should	 look	 out	 for	 any	 features	 that	 would	 be	 “atypical”	 for	 the	 proposed	diagnosis.	Our	results	reinforce	previous	proposals	to	implement	a	4-step	approach	based	on	age	at	onset,	 tempo	of	progression,	 family	history	and	associated	clinical	 features,	 to	improve	diagnostic	accuracy	[6].	
Nearly	 half	 of	 our	 patients	 fulfilling	 the	 criteria	 for	 one	 of	 the	 APs	 showed	 additional	“atypical”	 features	 on	 close	 scrutiny.	 While	 in	 some	 cases	 this	 led	 to	 re-consider	 the	diagnosis,	 in	a	substantial	proportion	of	our	series	the	diagnosis	could	not	be	revised.	It	should	be	remarked	that	we	recorded	some	clinical	features	as	being	atypical	on	the	basis	of	AP	research	criteria	(e.g.,	either	because	they	were	reported	as	exclusion	criteria	or	not	mentioned	 at	 all).	However,	 a	 body	of	 evidence	has	been	produced	 that	 such	 exclusion	criteria	 can	 in	 fact	 occur	 in	 some	 patients	 and	 should	 not	 be	 considered	 exclusive	anymore.	For	instance,	the	NNIPPS	criteria	for	PSP	consider	the	presence	of	a	rest	tremor	as	an	exclusion	criterion	for	the	diagnosis	of	PSP	[10,11],	while	it	is	nowadays	well	known	that	 PSP	 patients	 might	 have	 rest	 tremor	 (PSP-P)	 [17].	 Similarly,	 both	 NINDS	 or	 the	NNIPPS	sets	of	criteria	for	PSP	consider	signs	of	CBS,	 including	alien	limb	phenomenon,	apraxia	 and	 severe	 asymmetric	 parkinsonism,	 as	 exclusion	 criteria	 [10,11].	 However,	 a	
	recent	study	on	100	pathological	PSP	cases	has	shown	that	up	to	7%	can	present	with	a	PSP-CBS	overlap	phenotype	[18].		
For	other	clinical	features,	it	is	unclear	whether	they	might	occur	or	not	in	the	context	of	each	 AP.	 For	 instance,	 we	 found	 that	 up	 to	 18%	 of	 MSA	 patients	 (2/11	 of	 patients	 in	groups	A1	and	A2;	supplementary	figure	1B)	showed	evidence	of	cortical	involvement	(1	with	cognitive	impairment,	on	formal	neuropsychometry	and	1	with	visual	hallucinations	unrelated	to	medications).	Dementia	is	still	considered	an	exclusion	criterion	for	MSA,	but	a	 recent	 paper	 discussed	 that	 they	 indeed	 can	 have	 a	 certain	 degree	 of	 cognitive	impairment	 later	 in	 disease	 course	 [19].	 It	 remains	 to	 be	 seen	 how	 early	 cognitive	impairment	 can	 occur	 in	 MSA.	 As	 for	 the	 PSP	 group,	 we	 found	 that	 about	 one	 third	showed	 cerebellar	 signs	 (including	 limb	 ataxia,	 dysmetria	 and	 cerebellar	 eye	movements).	Cerebellar	signs	are	not	classically	seen	 in	 this	condition,	but	a	number	of	recent	 reports	 have	 provided	 clinical,	 imaging	 and	 pathological	 evidence	 of	 cerebellar	involvement	in	PSP	[20-22].	Once	again,	future	research	should	clarify	if	this	represents	a	novel	phenotype	of	PSP	(e.g.	PSP-C)	or	not.			
Altogether,	our	results	argue	for	an	update	of	the	current	criteria	that,	although	originally	not	meant	to	be	used	in	routine	clinical	practice,	do	not	seem	to	reflect	the	heterogeneity	of	each	AP.	A	first	attempt	has	been	in	fact	pursued	with	corticobasal	degeneration	(CBD)	[9],	where:	1)	it	is	advised	to	use	the	label	CBS	rather	than	CBD;	and	2)	different	criteria	exist	for	CBS	diagnosis,	profiled	according	to	the	different	phenotypes	presented.			
A	final	comment	is	also	needed	on	the	DaTSCAN	results.	In	a	number	of	patients	fulfilling	the	 criteria	 for	 a	 particular	 AP,	 DaTSCAN	 were	 negative,	 suggesting	 they	 had	 an	alternative	 diagnosis.	 However,	 we	 did	 not	 use	 this	 evidence	 per	 se	 to	 discard	 the	diagnosis,	since	there	is	increasing	evidence	that	a	minority	of	patients	with	degenerative	
	parkinsonism,	particularly	CBS	and	MSA-C,	might	 in	 fact	have	negative	scans	 [23-26].	 It	remains	to	be	seen	whether	this	is	the	case	in	large,	pathologically	proven,	series	of	APs.	
Whilst	 at	 one	 end	 of	 the	 spectrum	 there	 were	 patients	 fulfilling	 some	 AP	 criteria	 but	proven	to	have	a	different	condition,	at	the	other	end	there	were	patients	not	fulfilling	the	research	criteria,	but	being	still	considered	to	have	that	particular	AP.	One	example	would	be	the	patient	with	pathologically	proven	PSP,	who	at	the	time	of	our	first	assessment	did	not	 fulfil	 either	 the	 NINDS	 (lack	 of	 falls	 within	 the	 first	 year)	 or	 the	 NNIPPS	 (lack	 of	supranuclear	gaze	palsy)	criteria.	 	This	confirms	that	such	criteria	have	a	relatively	 low	sensitivity,	especially	early	in	the	disease	course	[2,27-29].	In	our	series,	this	might	have	been	 the	 case	 in	 up	 to	 19%.	 	 Early	 identification	 of	 these	 patients	 is	 indeed	 crucial	 in	terms	 of	 possible	 neuroprotective	 trials	 and	 this	 would	 reinforce	 the	 unmet	 need	 for	diagnostic	biomarkers.	Quite	obviously,	the	identification	of	possible	biomarkers	for	any	APs,	 would	 be	 possible	 only	 if	 we	 are	 able	 to	 select	 homogenous	 groups	 which	 truly	reflect	distinct	disease	entities.		
We	acknowledge	some	 limitations.	First,	our	study	was	retrospective,	and	some	clinical	features	might	be	unrecorded	or	overlooked.	Moreover,	ours	is	a	tertiary	referral	center	for	movement	disorders,	which	probably	biases	referrals	more	towards	“atypical”	cases.	It	may	also	be	the	case	that	some	of	the	“atypical”	patients	(e.g.	groups	A2)	could	actually	have	other,	yet	undefined,	conditions.	However	diagnoses	were	made	by	clinicians	with	significant	 expertise	 in	 the	 field.	 We	 classified	 our	 series	 according	 to	 the	 currently	available	 research	 criteria,	 some	of	which	are	 in	need	of	updating,	 and	which	were	not	developed	 for	 use	 in	 routine	 clinical	 settings.	 However,	 this	 seemed	 to	 us	 the	 only	systematic	approach	to	address	this	 topic.	Since	 for	a	 large	proportion	of	our	patients	a	
	conclusive	 (either	 genetic	 or	 pathological)	 diagnosis	 was	 not	 available,	 definitive	conclusions	cannot	be	drawn.	
Despite	 these	 limitations,	our	preliminary	results	underpin	 the	clinical	and	pathological	heterogeneity	 among	 atypical	 parkinsonian	 syndromes.	 While	 future,	 prospective,	multicenter	 studies	 with	 confirmatory	 pathological	 diagnosis	 are	 needed,	 it	 would	probably	 be	 wise,	 from	 the	 clinical	 standpoint,	 to	 start	 using	 the	 AP	 templates	 as	phenotypic	descriptors	rather	than	diagnostic	labels.	This	change	in	terminology	has	been	already	applied	to	CBS,	where	we	no	longer	refer	to	the	underlying	pathology.	Following	this	 line,	 it	might	be	also	useful	 to	start	using	the	concept	of	 typical	(and	atypical)	DLB,	MSA,	PSP	and	CBS.	 Such	a	pragmatic	 approach	might	be	useful	 to	 identify	homogenous	groups	of	patients	in	whom	to	search	for	reliable	biomarkers.		
Figure	caption		
Figure	1.	Flowchart	describing	the	study	design.	A)	Clinical	data	at	the	first	evaluation;	B)	Clinical	and	investigation	data	collected	throughout	a	mean	follow-up	period	of	1.5	years.		
Figure	 2.	Distribution	of	patients	 fulfilling	either	NINDS	or/and	NNIPPS	criteria	 for	 the	diagnosis	of	PSP.	
Supplementary	 figure	 1	 shows	 the	 sub-division	 of	 the	 patients	 for	 each	 AP,	 namely	Dementia	 with	 Lewy	 Bodies	 (1A),	 Multiple	 System	 Atrophy	 (1B),	 Progressive	Supranuclear	Palsy	(1C)	and	Corticobasal	Syndrome	(1D).	
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